Steve Bryson, PhD, science writer —

The incidence of ANCA-associated vasculitis (AAV) in southern Sweden was stable over a 23-year period, while its prevalence, the total number of cases overall, increased, a study showed. Stable incidence, or the same number of new cases per year, with a higher prevalence “might indicate better management and treatment…

A specific variant in both copies of the gene that codes for proteinase 3 (PR3) — one of the most common targets of ANCA-associated vasculitis (AAV)-driving antibodies — is linked to a nearly five times higher risk of severe relapse in people with PR3-associated AAV, a study found. While…

The European Alliance of Associations for Rheumatology (EULAR) has updated its recommendations on managing ANCA-associated vasculitis (AAV) based on new research and clinical data. Four overarching principles were introduced — the importance of patient-physician joint decisions, disease education, routine screening for treatment side effects and additional medical conditions,…

Concerns about the future, their disease’s social and emotional impact, and bodywide symptoms were prominent among those reported by ANCA-associated vasculitis (AAV) patients with low disease activity in a survey study from Mexico. People were responding to the AAV patient-reported outcomes (AAV-PRO) questionnaire, and its specific domains were found to associate…

Tavneos (avacopan) effectively reverses severe kidney disease associated with ANCA-associated vasculitis (AAV) compared with standard steroid therapy, according to a subgroup analysis of the Phase 3 ADVOCATE clinical trial. Greater improvements in kidney function with Tavneos were sustained for the two months of follow-up after the treatment stopped.

Patients with ANCA-associated vasculitis (AAV) have a higher risk of mortality than the general population, especially those who are older or have impaired kidney function, a long-term outcome analysis study has found. Infections were the leading cause of death, with treatment complications, such as immunosuppression and blood vessel inflammation,…

The CoronaVac COVID-19 vaccine has an excellent safety profile, but generates only a moderate immune response in people with ANCA-associated vasculitis (AAV), a clinical trial analysis found. Although the levels of vaccine-induced antibodies against SARS-CoV-2, the virus that causes COVID-19, declined over six months, a booster shot was shown…

Intensive care stays are more likely if oxygen-carrying hemoglobin levels are low at hospital admission in adults with kidney disease caused by ANCA-associated vasculitis (AAV), an analysis of medical records found. Severe kidney injury was the primary reason for intensive care unit (ICU) admission in these patients and associated…

In the year before being diagnosed with ANCA-associated vasculitis (AAV), Medicare beneficiaries had significantly higher use and costs of healthcare than those without AAV, an analysis found. According to researchers, earlier identification of AAV is necessary to provide patients with appropriate care and potentially reduce costs and healthcare use.

Amgen is the new owner of Tavneos (avacopan), an approved ANCA-associated vasculitis (AAV) therapy, following its successful $3.7 billion cash acquisition of ChemoCentryx. “ChemoCentryx enhances Amgen’s leading inflammation and nephrology portfolio and includes Tavneos (avacopan), a first-in-class treatment for severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis), an…